Haduvio™:  Relief is Possible

We are developing Haduvio™ (nalbuphine ER) unlocking new market opportunities and the potential to significantly improve the quality of life of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions.

Passionate about Progress

Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.

Passionate about Progress

Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.

Are you suffering from or caring for someone with symptoms associated with chronic neurologically mediated conditions?

A New Hope for Patients with Chronic and Serious Neurologically Mediated Conditions

We are developing Haduvio™ as an oral treatment for a broad range of chronic conditions for which patients have few, if any, treatment options. With its unique dual mechanism of action, Haduvio™ has the potential to significantly improve the quality of life of patients.

Committed to Excellence in Pharmaceutical Development and Bringing Solutions to Patients

news

10/21/2020

Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF Phase 2b/3 PRISM Trial of Haduvio for Severe Pruritus in Patients with Prurigo Nodularis   Reaches 50% Enrollment Milestone NEW HAVEN, Conn. , Oct. 21, 2020 (GLOBE NEWSWIRE) --   Trevi Therapeutics, Inc.

10/13/2020

Expands Management Team to Support Clinical Development and Commercial Strategy of Haduvio™ in Multiple Late Stage Programs NEW HAVEN, Conn. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and

09/09/2020

NEW HAVEN, Conn. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management

contact

Trevi Therapeutics

195 Church Street, 14th Floor
New Haven, CT 06510
map

(203) 304-2499
email us